Merck's Diabetes Drug Effective With Metformin in Study
Posted on: Thursday, 14 September 2006, 15:01 CDT
Merck & Co has announced that data from its phase III study of investigational diabetes drug Januvia used in conjunction with metformin significantly lowered glucose levels in patients.
Januvia is an investigational once-daily medicine that, if approved, would potentially be the first in a new class of oral drugs in the US that enhance the body's natural ability to lower blood sugar (glucose) when it is elevated. Data from the latest study shows that the drug was well tolerated and showed no meaningful differences in tolerability compared to metformin alone, Merck said.
"The significant glucose-lowering efficacy seen in this study suggests complementary mechanisms of action of sitagliptin and metformin resulting in an additive effect when both agents are given together," said Dr Barry Goldstein, study investigator.
"These results demonstrated that giving sitagliptin and metformin together was well tolerated with significantly greater efficacy than metformin alone, a mainstay of current diabetes treatment," he continued.
Source: Datamonitor
Related Articles
- New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions
- New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
- Five New Studies at Major Medical Meeting Further Demonstrate Clinical Experience for JANUVIA(TM) (Sitagliptin)
- New Data Released at Major Diabetes Meeting on Initial Combination Therapy With JANUVIA(TM) (Sitagliptin), Merck's Diabetes Medicine, and Metformin Through Two Years of Treatment
- Newly Released Phase III Studies for JANUVIA(TM), Merck's Investigational Once-Daily Medicine for Type 2 Diabetes, Showed Significantly Reduced Blood Sugar Levels When Used As Monotherapy or As Add-On Treatment
- Metformin Administration Modulates Neurosteroids Secretion in Non- Obese Amenorrhoic Patients With Polycystic Ovary Syndrome
- Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study
- Impact of Metformin on Glucose Metabolism in Nondiabetic, Obese African Americans
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
- Effect of Metformin on the Clinical and Metabolic Assessment of Women With Polycystic Ovary Syndrome
 |
 |
User Comments (0)
RSS Feeds